Compare DoorDash Inc (DASH) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Pfizer Inc — how do they compare? DoorDash Inc trades at $191.03 (market cap $83.07B), while Pfizer Inc trades at $27.93 (market cap $158.56B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays a 6.18% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and Pfizer Inc for 158 Days on average.
| DASH | PFE | |
|---|---|---|
Market Cap | $83.07B | $158.56B |
Volume | 3,242,567 | 44,138,282 |
Sector | Media | Health |
52-Week High | $275.44 | $29.02 |
52-Week Low | $146.60 | $23.67 |
Typical Hold Time | 59 Days | 158 Days |
Enterprise Value | $81.03B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $191.24, down 1.23% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth, reaching $13.72 billion in 2025, and achieved profitability with a net income margin of 6.81%. Recent developments include the launch of AI-powered text ordering and drone delivery expansion, signaling innovation in its core delivery business.
The outlook is positive with a consensus price target of $255.80, though high valuation multiples and mixed quarterly earnings misses pose risks. Investor sentiment is bolstered by analyst optimism, but regulatory scrutiny and competitive pressures remain key concerns for sustained growth.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
